OBJECTIVE
have greater arterial stiffness than their lean (age-, sex-, and race-matched) counterparts, suggesting the risk for a premature onset of CVD (6) .
25-Hydroxyvitamin D (25[OH]D)
has an established role in calcium and phosphorus metabolism and bone health. Recent discovery of 25 [OH]D receptors and the enzyme that converts 25 [OH]D to its active form in vascular smooth muscle and endothelial cells points to a role in vascular health as well (7) . 25 [OH]D has been shown to have antiproliferative effects in both vascular endothelial and smooth muscle cells. Furthermore, 25 [OH]D limits monocyte and macrophage differentiation and the release of inflammatory cytokines, blunting the inflammatory response, a known mediator of vascular disease (8) . Finally, to support the causality of this association, vitamin D receptor 2/2 mice exhibit site-specific accelerated atherogenesis (9) . As a result, recent studies have focused on the association between low 25[OH]D and vascular health. Studies in healthy, obese, and T2DM adults have found that low serum 25 [OH]D levels are associated with increased arterial stiffness (10) (11) (12) (13) . The role of 25 [OH]D in arterial stiffness has not been examined in high-risk youth, namely those with obesity and those with T2DM who are at risk for low levels of 25 [OH]D secondary to decreased sun exposure and excessive storage of 25 [OH]D in the adipose tissue (14) .
The purpose of this study was to examine the association between serum 25 [OH]D levels and arterial stiffness in youth and to determine if the relationship between 25 [OH]D levels and arterial stiffness differs by group. We hypothesized that low serum 25 [OH]D levels would be associated with increased arterial stiffness independent of traditional cardiovascular risk factors.
RESEARCH DESIGN AND METHODS

Study Population
The population for this analysis was drawn from individuals who participated in the National Institutes of Health-funded study Cardiovascular Disease in Adolescents with Type 2 Diabetes (T2CVD) at Cincinnati Children's Hospital Medical Center from 2004 to 2010 (15, 16) . In brief, the T2CVD study consisted of three groups: 221 individuals with T2DM, 250 obese individuals without T2DM, and 261 lean individuals (nonobese individuals without T2DM). All participants were between 10 and 24 years old at recruitment. Individuals with diabetes were islet cell antibody negative (glutamic acid decarboxylase, ICA512, and insulin autoantibodies), had no evidence of another specific type of diabetes, and did not require insulin in the basal state to prevent diabetic ketoacidosis. Each participant with T2DM was matched to at least one lean (BMI ,85th percentile) and one obese control (BMI $95th percentile) by age, race, and sex. All obese subjects underwent a 2-h oral glucose tolerance test to rule out subclinical T2DM according to American Diabetes Association guidelines (17). Pregnant females were excluded from the study. Prior to enrollment in T2CVD, written informed consent was obtained from subjects $18 years old or the parent or guardian for subjects ,18 years old. Written assent was also obtained for subjects ,18 years old according to the guidelines established by the institutional review board at Cincinnati Children's Hospital. The institutional review board granted a waiver of consent for the current study.
The study population for the current study was established using power calculations. We determined that a total sample size of 570 (190 subjects from each of the three groups) would be able to detect group differences of at least 6 6 20 ng/mL in 25[OH]D with 90% power at a significance level of 0.05. Therefore, we randomly selected 190 subjects from each of the three subgroups.
Data Collection in T2CVD
After a 10-h overnight fast, participants in the T2CVD study were seen at an inperson study visit (6, 15) . Anthropometric measurements, venipuncture, blood pressure (BP), and arterial stiffness data were collected. Trained personnel obtained two measures of height (stadiometer; Veeder-Rood, Elizabethtown, NC) and weight (electronic scale; Health O Meter), with the average of each used in analyses. BMI was calculated as kilograms per meter squared. Waist circumference was measured to the nearest 0.5 cm using a flexible metal research tape twice and averaged according to a standardized research protocol from the National Heart, Lung, and Blood Institute (NHLBI) Growth and Health Study. Systolic and diastolic BP were measured according to the standards of the Fourth Report on Blood Pressure in Children (18). DXA was performed with a Hologic 4500A (Hologic, Bedford, MA). Standards correlating X-ray beam attenuation to amount of lean and fat mass have been developed and validated against the hydrodensitometry method, which has previously been established as the most valid measurement of lean body mass and fat mass (19) . Percent body fat was calculated as total body fat mass/total body mass 3 100.
Laboratory Data Collected in T2CVD
Plasma glucose was measured using a Hitachi model 704 glucose analyzer (Roche Hitachi, Indianapolis, IN) with intra-assay and interassay coefficients of variation of 1.2 and 1.6%, respectively. Plasma insulin was measured by radioimmunoassay using an anti-insulin serum raised in guinea pigs, 125 I-labeled insulin (Linco, St. Louis, MO), and a double antibody method to separate bound from free tracer. Assays of fasting plasma lipid profiles were performed in a laboratory that is NHLBI/Centers for Disease Control and Prevention standardized, with the LDL cholesterol concentration calculated using the Friedewald equation. C-reactive protein (CRP) was measured using a highsensitivity ELISA. HbA 1c was measured in red blood cells using high-performance liquid chromatography methods.
Present Study
For the current study, the following laboratory measures were performed on serum samples that had been stored at 2808C. (20) . 2) Basic metabolic profile was performed to ensure normal calciumphosphorus metabolism, renal function, albumin, and creatinine. Each was measured on the Roche 311 chemistry autoanalyzer. Glomerular filtration rate (GFR) was then calculated using the Schwarz formula [GFR (mL/min/1.73 m 2 ) = (0.41 3 height in cm)/serum creatinine in mg/dL]. None of the subjects had GFR ,60 mL/min/1.73 m 2 , and hence none were excluded from the study based on their renal function.
Vascular Measures Collected in T2CVD
Vascular function testing was conducted after 5 min of rest in the supine position. AIx and PWV were obtained using the SphygmoCor device (SphygmoCor SCOR-PVx System; Atcor Medical, Sydney, Australia). BrachD was measured using the DynaPulse Pathway instrument (Pulse Metric, Inc.).
A SphygmoCor tonometer was used to measure AIx, a measure of arterial stiffness and pulse wave reflections (6) . The tonometer was placed over the right radial artery and three measures of AIx were collected. A single value, calculated as an average of three AIx measurements, was used in the analysis. The pressure waves were calibrated using mean arterial BP and diastolic BP obtained in the same arm. The device then analyzed the pulse wave using a validated generalized transfer function. Since AIx is affected by heart rate (HR), all AIx values were adjusted to a standard HR of 75 bpm. Reproducibility studies in our laboratory demonstrated intraclass correlation coefficients between 0.7 and 0.9.
The SphygmoCor tonometer was also used to measure PWV, an additional measure of arterial stiffness (21) . The distance from a proximal artery (carotid) to the distal artery (femoral) was measured to the nearest 0.1 cm twice, averaged, and entered into the software. A tonometer was used to collect proximal and distal arterial waveforms gated by the R-wave on a simultaneously recorded electrocardiogram. PWV then was calculated as the distance from the carotid to distal path length divided by the time delay measured between the carotid and femoral waveforms reported in meters per second. Three recordings of PWV were obtained on each subject and were averaged. Repeat measures show a coefficient of variation of ,5.2%.
The DynaPulse Pathway instrument (Pulse Metric, Inc.) was used to measure BrachD (22 Table 1 lists the demographic, anthropometric, and laboratory data for all participants stratified by study group. There were no significant differences among the three groups in age, sex, and race. Fig. 2A and B, respectively. BrachD was not correlated with 25 [OH]D by group (data not shown), and therefore GLMs were not pursued.
RESULTS
GLM analysis (Table 2) showed that serum 25 [OH]D level was an independent risk factor for AIx in the T2DM group only such that an increase in serum 25 [OH]D by 3 ng/mL was associated with a 1% decrease in AIx. Other independent determinants of AIx in the group with T2DM were age, height, and diastolic BP z score. In combination, the above risk factors explained ;20% of the variance for AIx in the group with T2DM.
The GLM analysis for PWV showed that serum 25 [OH]D level was an independent risk factor for PWV in the lean group only (Table 2) , although this was a small effect. Other independent determinants of PWV in lean individuals were age, sex, systolic BP z score, TG-to-HDL ratio, and HR. This model explained ;37% of variance for PWV in the lean group. In all models, interactions between 25[OH]D and race and 25 [OH] D and HbA 1c were tested and were nonsignificant.
CONCLUSIONS
Our study found that low serum 25 [OH]D levels in youth with T2DM were negatively associated with arterial stiffness, measured by AIx, even after adjustment for demographic and traditional CVD risk factors. Furthermore, we show that in youth with T2DM, a higher 25[OH]D level of 3 ng/mL is associated with a decrease in AIx of 1%. Considering that AIx in the group with T2DM was 5.7 6 12.0% (mean 6 SD), an absolute change of 1% may have a large impact on future cardiovascular outcomes given that an increase in arterial stiffness is known to predict future myocardial infarction and stroke (5, 25) .
Recent epidemiologic studies in adults have shown an inverse association (14) .
Our linear regression models showed that after adjustment for risk factors, serum 25 [OH]D level had a significant negative association with PWV in lean individuals and with AIx in participants with T2DM. In the obese group, although we found no association between 25 First, each measure of arterial stiffness, although all reliable, assesses a different aspect of the vasculature. This is the advantage of using the three independent measurements. PWV, a measure of central arterial stiffness, is considered the gold standard measure of subclinical arterial stiffness in both adults and children and has been shown to predict future cardiovascular events and mortality (32, 33) . AIx is a mixed measure of arterial stiffness that is influenced by central stiffness (PWV) and peripheral wave reflections (21) and has also been shown to predict all-cause mortality in adults with end-stage renal disease (34) and hypertension (5) . BrachD is a nonultrasound measure of stiffness (arterial compliance) in a medium muscular artery (4) and is highly correlated with cardiovascular risk factors (4). Differential associations between risk factors and arterial stiffness have been documented previously (6, 35) , because although the arterial stiffness measures are correlated, each assesses a different property of the arterial tree. Second, since 25[OH]D is known to limit the release of inflammatory cytokines (8) and suppress the renin aldosterone axis (28) , it is possible that the lower 25 [OH]D concentrations observed in T2DM have a larger effect on the vasculature. Confirmatory studies are needed in a larger cohort of adolescents with T2DM.
A recent study in T1DM youth found an association between serum 25[OH]D levels and PWV after adjusting for age, sex, race, and season. However, the relationship was no longer significant after adjusting for BMI z score, lipids, and BP (36) . In contrast, we found that 25[OH]D was independently associated with arterial stiffness in lean individuals and individuals with T2DM after adjusting for adiposity (waist to height), lipids, and BP. Our study and the T1DM study have some important differences to explain the discrepant results. First, 25 [OH]D levels were much lower in this group with T2DM compared with the previously published group with T1DM. Second, in contrast to the T1DM study, where PWV alone was reported as a marker of arterial stiffness, we studied the relationship between 25 [OH]D levels (20) .
Arterial stiffness is an important predictor of increased cardiovascular risk. Prior studies have shown that youth with obesity and T2DM have increased arterial stiffness, suggesting that they are at higher risk for early CVD (6) . However, conventional cardiovascular risk factors do not fully explain the observed differences in arterial stiffness among lean and obese individuals and individuals with T2DM (6) . The data presented here suggest that 25 [OH]D may be one of the nontraditional cardiovascular risk factors that contribute to arterial stiffness. Further randomized controlled trials in youth are needed to establish the causation and mechanism by which 25 [OH]D affects arterial stiffness and to establish whether supplementation in this group may reduce, or slow, the process of arterial stiffness to some extent.
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